Quantcast
Last updated on April 16, 2014 at 6:17 EDT

Latest P53 Stories

2012-07-03 10:22:20

High risk and better outcome for glioma wrapped up in rare gene variant Researchers at Moffitt Cancer Center working with colleagues at three other institutions have validated a link between a rare genetic variant and the risk of glioma, the most common and lethal type of brain tumor. The validation study also uncovered an association between the same rare genetic variant and improved rates of survival for patients with glioma. The study, the first to confirm a rare susceptibility...

2012-06-25 23:10:34

Prions, the causal agents of Mad Cow and other diseases, are very unique infectious particles. They are proteins in which the complex molecular three-dimensional folding process just went astray. For reasons not yet understood, the misfolding nature of prions is associated to their ability to sequester their normal counterparts and induce them to also adopt a misfolding conformation. The ever-growing crowd of misfolded proteins form the aggregates seen in diseases such as Parkinson's and...

2012-06-11 21:37:06

Mutated tumor suppressor gene p53 leads to better results Presence of normal p53, a tumor suppressor gene, instead of a mutated version, makes breast cancer chemotherapy with doxorubicin less effective. The preclinical study led by MD Anderson scientists was published today in the journal Cancer Cell. The research, which challenges the existing paradigm, is another step closer to personalized cancer medicine for breast cancer. "It's really important to understand the genetic defects...

2012-06-02 02:20:16

CHICAGO, June 2, 2012 /PRNewswire/ -- -- TLE3 Biomarker Over-expressed in HER2-positive, Hormone Receptor-positive, and Triple-negative Breast Cancers -- -- EGFR status May Facilitate Therapeutic Decision-making in Head and Neck Cancer -- Caris Life Sciences announced today the utility of the company's Caris Target Now(TM) evidence-based molecular profiling service in the characterization of breast and head and neck cancers. These data were presented today at the...

2012-05-14 22:39:36

A new study describes a compound that selectively kills cancer cells by restoring the structure and function of one of the most commonly mutated proteins in human cancer, the "tumor suppressor" p53. The research, published by Cell Press in the May 15th issue of the journal Cancer Cell, uses a novel, computer based strategy to identify potential anti-cancer drugs, including one that targets the third most common p53 mutation in human cancer, p53-R175H. The number of new cancer patients...

2012-05-08 02:28:00

NATICK, Mass., May 8, 2012 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announces that co-founder Ronald A. DePinho MD, President of MD Anderson Cancer Center, has been appointed to the National Academy of Sciences. (Logo: http://photos.prnewswire.com/prnh/20120508/NE02031LOGO ) Dr. DePinho has been a pioneer in cancer research for over 20 years. His laboratory has produced an array of discoveries including improved mouse models...

2012-05-07 02:31:49

TUCSON, Ariz., May 7, 2012 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VENTANA Companion Algorithm p53 (DO-7) image analysis application using the VENTANA iScan Coreo Au scanner and VIRTUOSO software. Currently, Ventana is the only company offering an FDA-cleared p53 image analysis algorithm for determining p53 expression levels in breast cancer patients. Ventana is...

2012-04-26 23:54:58

Researchers trace influence via mouse model that allows oncogene to be turned on and off A genetic mutation that drives the initiation of pancreatic cancer also manipulates metabolic pathways to support tumor growth and progression, scientists report in the journal Cell. This newly discovered role for the Kras oncogene opens up a new category of potential targets for thwarting the influential mutation, which has proved difficult to attack directly, said study co-lead author Haoqiang...

2012-04-23 21:08:38

St. Jude Children's Research Hospital scientists discovered that the protein TopBP1 is indispensable for preventing the accumulation of DNA damage early in brain formation and might also serve as a tumor suppressor St. Jude Children's Research Hospital scientists have rewritten the job description of the protein TopBP1 after demonstrating that it guards early brain cells from DNA damage. Such damage might foreshadow later problems, including cancer. Researchers showed that cells in the...

2012-04-23 06:27:37

St. Jude Children's Research Hospital scientists discovered that the protein TopBP1 is indispensible for preventing the accumulation of DNA damage early in brain formation and might also serve as a tumor suppressor MEMPHIS, Tenn., April 23, 2012 /PRNewswire-USNewswire/ -- St. Jude Children's Research Hospital scientists have rewritten the job description of the protein TopBP1 after demonstrating that it guards early brain cells from DNA damage. Such damage might foreshadow later...